Clinical Trials Logo

RAS Wild Type clinical trials

View clinical trials related to RAS Wild Type.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04561336 Completed - Clinical trials for Metastatic Colorectal Cancer

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Start date: August 10, 2018
Phase: Phase 2
Study type: Interventional

This is a non-profit phase II, open-label, single-arm study of cetuximab plus avelumab in patients with RAS WT mCRC treated in first line with chemotherapy in combination with an anti- EGFR drug that have had a clinical benefit (complete or partial response) from treatment.

NCT ID: NCT03043950 Completed - Clinical trials for Metastatic Colorectal Cancer

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

VALIDATE
Start date: January 25, 2017
Phase:
Study type: Observational

A safety and efficacy study of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting (VALIDATE)

NCT ID: NCT02292758 Completed - Clinical trials for Colorectal Adenocarcinoma

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Start date: December 12, 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally advanced/metastatic) and cannot be removed by surgery. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as cetuximab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving irinotecan and cetuximab with or without bevacizumab may work betting in treating patients with colorectal cancer.